MA45235A - Anticorps anti-c5 et leurs utilisations - Google Patents

Anticorps anti-c5 et leurs utilisations

Info

Publication number
MA45235A
MA45235A MA045235A MA45235A MA45235A MA 45235 A MA45235 A MA 45235A MA 045235 A MA045235 A MA 045235A MA 45235 A MA45235 A MA 45235A MA 45235 A MA45235 A MA 45235A
Authority
MA
Morocco
Prior art keywords
antibodies
Prior art date
Application number
MA045235A
Other languages
English (en)
Other versions
MA45235B1 (fr
Inventor
Ying Hu
Adrianna Latuszek
William Olson
Carmelo Romano
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA45235A publication Critical patent/MA45235A/fr
Publication of MA45235B1 publication Critical patent/MA45235B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
MA45235A 2016-06-14 2017-06-13 Anticorps anti-c5 et leurs utilisations MA45235B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662349705P 2016-06-14 2016-06-14
US201662405561P 2016-10-07 2016-10-07
US201662422107P 2016-11-15 2016-11-15
EP17731785.6A EP3468990B1 (fr) 2016-06-14 2017-06-13 Anticorps anti-c5 et leurs utilisations
PCT/US2017/037226 WO2017218515A1 (fr) 2016-06-14 2017-06-13 Anticorps anti-c5 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA45235A true MA45235A (fr) 2019-04-17
MA45235B1 MA45235B1 (fr) 2024-07-31

Family

ID=59091673

Family Applications (2)

Application Number Title Priority Date Filing Date
MA45235A MA45235B1 (fr) 2016-06-14 2017-06-13 Anticorps anti-c5 et leurs utilisations
MA71118A MA71118B1 (fr) 2016-06-14 2017-06-13 Anticorps anti-c5 et leurs utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA71118A MA71118B1 (fr) 2016-06-14 2017-06-13 Anticorps anti-c5 et leurs utilisations

Country Status (30)

Country Link
US (4) US10633434B2 (fr)
EP (3) EP4706763A3 (fr)
JP (4) JP7102353B2 (fr)
KR (3) KR20240070728A (fr)
CN (3) CN109563159B (fr)
AU (2) AU2017283470B2 (fr)
CA (1) CA3027487A1 (fr)
CL (1) CL2018003563A1 (fr)
CO (1) CO2018014413A2 (fr)
DK (1) DK3468990T3 (fr)
ES (2) ES3069813T3 (fr)
FI (2) FI4374922T3 (fr)
HR (2) HRP20260641T1 (fr)
HU (1) HUE067224T2 (fr)
IL (3) IL263481B2 (fr)
LT (2) LT3468990T (fr)
MA (2) MA45235B1 (fr)
MD (2) MD4374922T2 (fr)
MX (3) MX2018015149A (fr)
MY (3) MY196006A (fr)
PH (2) PH12018502560B1 (fr)
PL (2) PL4374922T3 (fr)
PT (2) PT4374922T (fr)
RS (2) RS68096B1 (fr)
SG (2) SG10202012243VA (fr)
SI (2) SI4374922T1 (fr)
SM (2) SMT202400269T1 (fr)
UA (1) UA124734C2 (fr)
WO (1) WO2017218515A1 (fr)
ZA (1) ZA201808171B (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (fr) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Procédés de régulation de la pharmacocinétique sanguine d'anticorps
EP3127921A1 (fr) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
PY09026846A (es) * 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
PT2970974T (pt) 2013-03-14 2017-11-29 Alnylam Pharmaceuticals Inc Composições de irna de componente do complemento c5 e métodos para a sua utilização
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
CA3024618A1 (fr) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Procedes de traitement de la myasthenie grave generalisee refractaire
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
EP3592386A4 (fr) * 2017-03-06 2021-01-13 The Trustees Of The University Of Pennsylvania Anticorps anti-c5 et leurs utilisations
ES2965486T3 (es) 2017-07-27 2024-04-15 Alexion Pharma Inc Formulaciones de anticuerpos anti-C5 de alta concentración
EP3694545A4 (fr) 2017-10-11 2021-12-01 Board Of Regents, The University Of Texas System Anticorps pd-l1 humains et leurs procédés d'utilisation
JP7518764B2 (ja) * 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
AU2018383751B2 (en) * 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
US20190247560A1 (en) * 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
EP3768723A4 (fr) 2018-03-23 2021-12-29 Board of Regents, The University of Texas System Anticorps à double spécificité pour pd-l1 et pd-l2 humains et leurs procédés d'utilisation
US11976128B2 (en) 2018-03-23 2024-05-07 Board Of Regents, The University Of Texas System Human PD-L2 antibodies and methods of use therefor
EP4501355A3 (fr) 2018-03-23 2025-04-30 Board Of Regents, The University Of Texas System Anticorps à double spécificité pour pd-l1 et pd-l2 et leurs procédés d'utilisation
US12410234B2 (en) 2018-04-26 2025-09-09 The Trustees Of The University Of Pennsylvania Compositions and methods for retrieving tumor-related antibodies and antigens
EP3802593B1 (fr) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosage et administration d'anticorps anti-c5 pour le traitement de l'hémoglobinurie paroxystique nocturne (pnh) chez des patients pédiatriques
EP3802603A1 (fr) 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage et administration d'anticorps anti-c5 pour le traitement du syndrome hémolytique et urémique atypique (shua) chez des patients pédiatriques
JP7538723B2 (ja) 2018-06-28 2024-08-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体の産生方法
CN113038967B (zh) * 2018-09-06 2026-07-14 宾夕法尼亚大学理事会 人源化抗c5抗体及其用途
EP3852874A1 (fr) * 2018-09-17 2021-07-28 Kyoto University Administration d'un agent anti-c5 pour le traitement d'une lésion ou d'une insuffisance hépatique
US20200095307A1 (en) 2018-09-21 2020-03-26 Alexion Pharmaceuticals, Inc. Compositions and methods for the treatment of neuromyelitis optica
WO2020092546A1 (fr) 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Co-administration d'une hyaluronidase et d'un anticorps anti-c5 pour le traitement d'états associés au complément
US12240893B2 (en) 2018-10-30 2025-03-04 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
JP7511566B2 (ja) 2019-01-25 2024-07-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与
MX2021009789A (es) 2019-02-14 2021-11-17 Alexion Pharma Inc Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de miastenia gravis generalizada.
WO2020242849A1 (fr) 2019-05-24 2020-12-03 Alexion Pharmaceuticals, Inc. Procédés de traitement du vitiligo à l'aide d'un anticorps anti-c5
US20220259305A1 (en) 2019-08-05 2022-08-18 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis with eculizumab
WO2021034639A1 (fr) * 2019-08-16 2021-02-25 Regeneron Pharmaceuticals, Inc. Formulations d'anticorps anti-c5 à concentration élevée
US20220356234A1 (en) 2019-10-02 2022-11-10 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
MX2022004712A (es) * 2019-10-25 2022-08-04 Regeneron Pharma Regimenes de dosificacion para tratar o prevenir enfermedades asociadas a c5.
EP4061400A4 (fr) * 2019-11-20 2024-01-10 Cornell University Génération de cellules endothéliales spécifiques du glomérule rénal et procédés d'utilisation
CA3161271A1 (fr) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Anticorps anti-c5 pour le traitement de trouble du spectre de la neuromyelite optique
US20230043576A1 (en) 2019-12-23 2023-02-09 Alexion Pharmaceuticals, Inc. Methods of treating pregnancy-associated atypical hemolytic uremic syndrome using an anti-c5 antibody
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN111234016B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的全人源单克隆抗体及应用
AU2020438234A1 (en) 2020-03-27 2022-09-29 Inflarx Gmbh Inhibitors of C5a for the treatment of corona virus infection
CN113563467A (zh) * 2020-04-28 2021-10-29 上海普铭生物科技有限公司 针对人补体蛋白c5的抗体及其应用
MX2022013606A (es) 2020-04-30 2023-01-16 Alnylam Pharmaceuticals Inc Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
KR20230009431A (ko) 2020-05-12 2023-01-17 알렉시온 파마슈티칼스, 인코포레이티드 발작성 야간 혈색소뇨증의 치료를 위한 보체 인자 d 저해제를 단독으로 또는 항-c5 항체와 조합한 용도
CN115667925A (zh) 2020-05-15 2023-01-31 阿雷克森制药公司 使用细胞外囊泡来检测补体激活的方法以及其用于评估和/或监测补体介导的疾病的治疗的用途
CN113754763B (zh) * 2020-06-05 2024-03-08 天辰生物医药(苏州)有限公司 分离的抗原结合蛋白及其用途
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下（sc）施用抗c5抗体治疗补体相关病症
WO2022011086A1 (fr) * 2020-07-09 2022-01-13 Alexion Pharmaceuticals, Inc. Dosage et administration d'anticorps anti-c5 pour le traitement de l'hémoglobinurie paroxystique nocturne (pnh) chez des patients pédiatriques
JP7821160B2 (ja) 2020-08-13 2026-02-26 アレクシオン ファーマシューティカルズ， インコーポレイテッド 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与
IL301350A (en) 2020-09-21 2023-05-01 Alexion Pharma Inc Dosage and administration of anti-c5 antibodies for treating c5-mediated glomerular nephritis (gn), including lupus nephritis (ln) and/or iga nephropathy (igan)
EP4232473A1 (fr) 2020-10-23 2023-08-30 Alexion Pharmaceuticals, Inc. Méthodes de traitement de patients atteints de troubles du complément à l'aide d'anticorps anti-c5
CA3173016A1 (fr) 2021-01-22 2022-07-28 Gin-Fu CHEN Methodes de traitement de la microangiopathie thrombotique a mediation par le complement a l'aide d'un anticorps anti-c5
CA3220629A1 (fr) 2021-05-28 2022-12-01 Tobin J. CAMMETT Procedes de detection de biomarqueurs cm-tma
MX2023015073A (es) 2021-06-14 2024-01-18 Alexion Pharma Inc Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la dermatomiositis (dm).
EP4370547A1 (fr) 2021-07-14 2024-05-22 Alexion Pharmaceuticals, Inc. Dosage et administration d'anticorps anti-c5 pour le traitement de la myasthénie gravis
WO2023023220A1 (fr) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la drépanocytose ou de la bêta-thalassémie à l'aide d'un inhibiteur de la voie alterne du complément
WO2023050233A1 (fr) * 2021-09-29 2023-04-06 The Trustees Of The University Of Pennsylvania Anticorps anti-c5a humanisés et leurs utilisations
EP4423271A2 (fr) 2021-10-28 2024-09-04 Regeneron Pharmaceuticals, Inc. Procédés et compositions associés à crispr/cas pour la désactivation de c5
AR127477A1 (es) 2021-10-29 2024-01-31 Alnylam Pharmaceuticals Inc COMPOSICIONES DE ARNi CONTRA EL FACTOR B DEL COMPLEMENTO (CFB) Y MÉTODOS DE USO DE LAS MISMAS
WO2023192976A1 (fr) 2022-04-01 2023-10-05 Board Of Regents, The University Of Texas System Anticorps à double spécificité dirigés contre pd-l1 et pd-l2 humains et leurs méthodes d'utilisation
US20260077039A1 (en) * 2022-08-30 2026-03-19 Longbio Pharma (Suzhou) Co., Ltd. Anti-human complement c5 antibody and fusion protein thereof
CA3266977A1 (fr) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. Profils de biomarqueurs de diagnostic et de pronostic chez des patients ayant une microangiopathie thrombotique associée à une greffe de cellules souches hématopoïétiques (hsct-tma)
TW202426048A (zh) 2022-09-06 2024-07-01 美商阿雷希昂製藥公司 用於治療造血幹細胞移植相關血栓性（ｈｓｃｔ－ｔｍａ）的抗ｃ５抗體的補充劑量和投與
TW202423479A (zh) 2022-09-28 2024-06-16 美商阿雷希昂製藥公司 用於預防或最小化患有慢性腎病的患者中的心臟手術相關急性腎損傷（csa-aki）和/或隨後的主要不良腎事件（make）的抗c5抗體之劑量及投與
WO2024238421A1 (fr) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Utilisation de biomarqueurs pour l'identification et le traitement de troubles médiées par le complément
WO2024238422A1 (fr) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Utilisation d'un panel de lectines pour la détection de biomarqueurs du complément dans des vésicules extracellulaires d'urine
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
IL327001A (en) 2024-02-02 2026-05-01 Alexion Pharma Inc Dosage and administration of anti-C5 antibodies for the treatment of IGA nephropathy (IGAN)
WO2025221479A1 (fr) 2024-04-16 2025-10-23 Alexion Pharmaceuticals, Inc. Biomarqueurs pour surveiller un traitement efficace d'un trouble du spectre de la neuromyélite optique (nmosd) avec des inhibiteurs du composant c5 du complément
US20260097063A1 (en) 2024-10-01 2026-04-09 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody/c5 irna dosing regimens for treating c5-associated diseases
WO2026112457A2 (fr) 2024-11-21 2026-05-28 Regeneron Pharmaceuticals, Inc. Molécules de liaison à l'antigène hétérodimères qui se lient à des particules virales et leurs utilisations
CN119409815B (zh) * 2025-01-07 2025-04-08 天辰生物医药(苏州)有限公司 抗人补体c5 vhh抗体及其应用

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
JPH06506604A (ja) 1991-07-15 1994-07-28 オクラホマ メディカル リサーチ ファウンデーション 自在なドナー細胞
WO1994000560A1 (fr) 1992-06-29 1994-01-06 Alexion Pharmaceuticals, Inc. Matrice de cellules endotheliales microvasculaires et donneuses universelles
AU2191795A (en) 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5562904A (en) 1994-07-21 1996-10-08 Alexion Pharmaceuticals, Inc. Retroviral transduction of cells using soluble complement inhibitors
AU3729295A (en) 1994-09-23 1996-04-09 Alexion Pharmaceuticals, Inc. Methods for the treatment of inflammatory joint disease
US6673346B1 (en) 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
ATE449791T1 (de) 2000-10-10 2009-12-15 Genentech Inc Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1878441B1 (fr) 2001-08-17 2018-01-24 Genentech, Inc. Inhibiteurs de chemin d'accès complémentaires liant C5 et C5a sans empêcher la formation de C5b
MXPA04001301A (es) 2001-08-17 2004-07-08 Tanox Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b.
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
EP1545611B1 (fr) 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Procede de traitement de l'asthme mettant en oeuvre des anticorps en complement du constituant c5
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
EP2669377A3 (fr) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Agents iARN modifiés
US7884188B2 (en) 2003-06-02 2011-02-08 Varleigh Immuno Pharmaceuticals (Vip) Ltd Complement inhibitors
US7199064B2 (en) 2003-09-08 2007-04-03 Matsushita Electric Industrial Co., Ltd. Plasma processing method and apparatus
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
EP1740946B1 (fr) 2004-04-20 2013-11-06 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
EP2338511A3 (fr) 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation du temps de survie d'une greffe allogénique par l'inhibition de l'activité du complément
US7763708B2 (en) 2004-08-12 2010-07-27 Institute For Protein Science Co., Ltd. Methods and compositions for modulating C5-a-mediated inflammatory responses
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
AU2013200223B2 (en) 2005-11-04 2015-08-20 Genentech, Inc. Use of Complement Pathway Inhibitors to Treat Ocular Diseases
BRPI0708424A2 (pt) 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
WO2008030505A2 (fr) 2006-09-05 2008-03-13 Alexion Pharmaceuticals, Inc. Procédés et compositions de traitement de neuropathies induites par des antibiotiques
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
EP2061501B1 (fr) 2006-09-08 2015-04-08 Volution Immuno Pharmaceuticals SA Procédé de traitement de troubles respiratoires
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
EP2148691B1 (fr) 2007-02-05 2015-05-20 Apellis Pharmaceuticals, Inc. Analogues de compstatin pour le traitement de conditions inflammatoires du système respiratoire
CL2008003241A1 (es) 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
US8229812B2 (en) 2009-01-28 2012-07-24 Headwater Partners I, Llc Open transaction central billing system
AU2014201433B2 (en) 2008-08-05 2016-05-26 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
PY09026846A (es) * 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
WO2010039690A1 (fr) 2008-09-30 2010-04-08 The Trustees Of The University Of Pennsylvania Procédé d’inhibition d’une activité procoagulante induite par des biomatériaux utilisant des inhibiteurs de compléments
US9891219B2 (en) 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
JP6223659B2 (ja) 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物
NZ597259A (en) 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
EP2454623A1 (fr) 2009-07-17 2012-05-23 Corning Cable Systems LLC Rubans de fibres optiques, et matériau de matrice pour rubans à faible teneur en oligomères
EP2327725A1 (fr) 2009-11-26 2011-06-01 InflaRx GmbH Groupes caractéristiques à liaison anti-C5a avec une activité à blocage élevé
CA2785612C (fr) 2010-01-08 2019-09-10 Varleigh Immuno Pharmaceuticals (Vip) Ltd. Ev576 pour utilisation dans traitement d'infections virales des voies respiratoires
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
WO2011109338A1 (fr) 2010-03-01 2011-09-09 Alexion Pharmaceuticals Inc. Méthodes et compositions pour le traitement de la maladie de degos
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
AU2011245117B2 (en) 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
AU2015201676B2 (en) 2010-04-30 2016-10-13 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
BR112012033119A2 (pt) * 2010-06-22 2016-10-25 Univ Colorado Regents anticorpos para o fragamento c3d do componente do complemento 3.
EP2699256B1 (fr) 2011-04-21 2017-09-27 The Regents of the University of Colorado, a body corporate Compositions et méthodes de traitement de maladie de devic
SG10201703249PA (en) 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
CA2866232A1 (fr) 2012-05-25 2013-11-28 Novartis Ag Composition pharmaceutique aqueuse contenant un agent therapeutique biologique et de la guanidine ou un derive de guanidine, et injection comprenant la composition
US9133269B2 (en) 2012-08-24 2015-09-15 Anaptysbio, Inc. Humanized antibodies directed against complement protein C5
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
BR112015018438A2 (pt) 2013-01-31 2017-07-18 Seoul Nat Univ R&Db Foundation anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
BR112015021979A2 (pt) * 2013-03-14 2017-08-29 Regeneron Pharma Anticorpos humanos para grem1
JP6505079B2 (ja) 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
ES2796078T3 (es) 2013-09-16 2020-11-25 Childrens Hospital Med Ct Composiciones y métodos para el tratamiento de la microangiopatía trombótica asociada al hsct
US20160237146A1 (en) 2013-10-07 2016-08-18 Massachusetts Eye And Ear Infirmary Methods of Preventing or Reducing Photoreceptor Cell Death
WO2015103438A2 (fr) 2014-01-02 2015-07-09 Genelux Corporation Traitement d'appoint par un virus oncolytique avec des agents qui augmentent l'infectivité du virus
US20170073754A1 (en) 2014-02-07 2017-03-16 Novartis Ag Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
CA3177696A1 (fr) 2014-02-20 2015-08-27 Allergan, Inc. Anticorps anti-composant c5 de du systeme de complement
BR112016017402A2 (pt) 2014-02-21 2017-10-17 Medimmune Ltd fusões anti-pcsk9~glp-1 e métodos para uso
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EA201691481A1 (ru) 2014-03-20 2017-02-28 Инфларкс Гмбх ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
MX2016014504A (es) 2014-05-05 2017-05-23 Regeneron Pharma Animales c5 y c3 humanizados.
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
JP6564776B2 (ja) 2014-07-12 2019-08-21 株式会社カネカ 複合太陽電池、太陽電池モジュール、および集光太陽電池
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
WO2016160756A2 (fr) 2015-03-31 2016-10-06 Alexion Pharmaceuticlas, Inc. Identification et traitement de sous-populations de patients souffrant d'hémoglobinurie paroxystique nocturne
US20180311299A1 (en) 2015-05-01 2018-11-01 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
WO2016200627A1 (fr) 2015-06-09 2016-12-15 Children's Hospital Medical Center Algorithme de dosage pour inhibiteur du complément
US20160362482A1 (en) 2015-06-10 2016-12-15 Case Western Reserve University Compositions and methods of modulating b cell response
EP3307316A1 (fr) 2015-06-12 2018-04-18 Alnylam Pharmaceuticals, Inc. Compositions d'arni de composant du complément c5 et leurs procédés d'utilisation
WO2017035362A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Utilisation de composés inhibiteurs de la voie du complément pour atténuer des réponses immunitaires indésirables associées à une thérapie adoptive par lymphocytes t
EP3328885A1 (fr) 2015-09-11 2018-06-06 Bruce Andrien Variants d'éculizumab et d'éculizumab glycosylé de recombinaison
US20180237509A1 (en) 2015-09-28 2018-08-23 Alexion Pharmaceuticals, Inc. Methods of treating adamts13 deficiencies and congenital thrombotic thrombocytopenia in pediatric patients
EP3359566A1 (fr) 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. Procédé pour le traitement de la dégénérescence maculaire liée à l'âge chez un patient
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
EP3368073B1 (fr) 2015-10-30 2024-05-15 Alexion Pharmaceuticals, Inc. Procédé d'inhibition d'exacerbations de vasculopathies d'allogreffe médiées par les cellules t
CN108401431B (zh) 2015-12-18 2022-01-25 中外制药株式会社 抗-c5抗体及使用方法
US20190023775A1 (en) 2016-01-11 2019-01-24 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
MA53248A (fr) 2016-01-25 2022-02-16 Takeda Pharmaceuticals Co Anticorps anti-c5 à commutation ph améliorée
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
CA3024618A1 (fr) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Procedes de traitement de la myasthenie grave generalisee refractaire
WO2017212391A1 (fr) 2016-06-07 2017-12-14 Novartis Ag Schéma posologique d'un anticorps anti-c5
CN109328197A (zh) 2016-06-07 2019-02-12 诺华股份有限公司 用于治疗具有补体c5多态性的患者的抗c5抗体
EP3469083A1 (fr) 2016-06-10 2019-04-17 Alnylam Pharmaceuticals, Inc. Compositions d'arni du composant c5 du complément et leurs méthodes d'utilisation pour traiter l'hémoglobinurie paroxystique nocturne (hpn)
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
SG10201800265UA (en) 2016-06-17 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
WO2018009588A1 (fr) 2016-07-06 2018-01-11 Macho Daisy Llc Dispositif portable et système pour messagerie audio personnelle
EP3512964B1 (fr) 2016-09-14 2021-12-15 The U.S.A. as represented by the Secretary, Department of Health and Human Services Méthodes de diagnostic et de traitement de déficience en cd55, d'hyperactivation du complément, de thrombose angiopathique et d'entéropathie à perte de protéine (chaple), une maladie orphelline nouvellement identifiée
JP7256741B2 (ja) 2016-10-12 2023-04-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性
US10802945B2 (en) 2016-12-07 2020-10-13 Ab Initio Technology Llc Differencing of executable dataflow graphs
AU2017376884B2 (en) 2016-12-16 2024-10-03 Samsung Bioepis Co., Ltd Stable aqueous anti-C5 antibody composition
TWI828672B (zh) 2017-01-31 2024-01-11 日商中外製藥股份有限公司 用於治療或預防c5相關疾病的醫藥組合物以及治療或預防c5相關疾病的方法
EP3592386A4 (fr) 2017-03-06 2021-01-13 The Trustees Of The University Of Pennsylvania Anticorps anti-c5 et leurs utilisations
MX2019011252A (es) 2017-03-23 2020-01-23 Univ Pennsylvania Anticuerpos anti-c5a y usos de los mismos.
JP2020517605A (ja) 2017-04-19 2020-06-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 腎臓移植の感作されたレシピエントにおける抗体媒介性拒絶の予防における抗ｃ５抗体の有効性
AU2018286754A1 (en) 2017-06-23 2019-12-19 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5A activity
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
WO2021034639A1 (fr) 2019-08-16 2021-02-25 Regeneron Pharmaceuticals, Inc. Formulations d'anticorps anti-c5 à concentration élevée

Also Published As

Publication number Publication date
AU2024204175A1 (en) 2024-07-11
EP4374922B1 (fr) 2026-02-25
US20170355757A1 (en) 2017-12-14
HRP20260641T1 (hr) 2026-07-03
UA124734C2 (uk) 2021-11-10
FI3468990T3 (fi) 2024-06-26
MA71118B1 (fr) 2026-04-30
US11479602B2 (en) 2022-10-25
MY196006A (en) 2023-03-06
WO2017218515A1 (fr) 2017-12-21
PT4374922T (pt) 2026-05-04
KR20190018166A (ko) 2019-02-21
LT3468990T (lt) 2024-06-25
IL324531A (en) 2026-01-01
IL263481A (en) 2019-01-31
CL2018003563A1 (es) 2019-02-22
MD4374922T2 (en) 2026-07-31
AU2017283470A1 (en) 2019-01-03
SG11201810933QA (en) 2019-01-30
JP7893940B2 (ja) 2026-07-22
HUE067224T2 (hu) 2024-10-28
IL309975A (en) 2024-03-01
IL263481B1 (en) 2024-02-01
US20230174631A1 (en) 2023-06-08
MY191668A (en) 2022-07-06
HRP20240815T1 (hr) 2024-09-27
US10633434B2 (en) 2020-04-28
PH12018502560B1 (en) 2023-11-15
PT3468990T (pt) 2024-06-25
MX2023001727A (es) 2023-02-22
CN116769024A (zh) 2023-09-19
IL309975B2 (en) 2026-04-01
MY196220A (en) 2023-03-23
IL309975B1 (en) 2025-12-01
PL4374922T3 (pl) 2026-06-08
SMT202600200T1 (it) 2026-05-12
EP4374922A2 (fr) 2024-05-29
CO2018014413A2 (es) 2019-03-08
NZ749153A (en) 2025-03-28
JP2025134088A (ja) 2025-09-16
MD3468990T2 (ro) 2024-11-30
MX2023001726A (es) 2023-02-22
US20200262900A1 (en) 2020-08-20
PH12018502560A1 (en) 2019-10-14
SG10202012243VA (en) 2021-01-28
NZ789069A (en) 2025-06-27
EP3468990A1 (fr) 2019-04-17
US11492392B2 (en) 2022-11-08
ES2984352T3 (es) 2024-10-29
SMT202400269T1 (it) 2024-07-09
KR20240070728A (ko) 2024-05-21
RS68096B1 (sr) 2026-06-30
ES3069813T3 (en) 2026-06-10
CN109563159A (zh) 2019-04-02
PH12023500007A1 (en) 2024-03-11
MX2018015149A (es) 2019-08-21
AU2017283470B2 (en) 2024-03-21
KR20230074831A (ko) 2023-05-31
JP7682964B2 (ja) 2025-05-26
MA45235B1 (fr) 2024-07-31
EP3468990B1 (fr) 2024-03-27
JP7368543B2 (ja) 2023-10-24
KR102667023B1 (ko) 2024-05-21
JP7102353B2 (ja) 2022-07-19
LT4374922T (lt) 2026-06-10
SI3468990T1 (sl) 2024-07-31
JP2019528039A (ja) 2019-10-10
FI4374922T3 (fi) 2026-05-13
CA3027487A1 (fr) 2017-12-21
PL3468990T3 (pl) 2024-08-05
JP2022106952A (ja) 2022-07-20
IL263481B2 (en) 2024-06-01
EP4374922A3 (fr) 2024-08-28
BR112018075875A2 (pt) 2019-03-19
ZA201808171B (en) 2026-04-29
DK3468990T3 (da) 2024-06-24
CN109563159B (zh) 2023-06-23
US20200262901A1 (en) 2020-08-20
SI4374922T1 (sl) 2026-06-30
JP2023175765A (ja) 2023-12-12
EP4706763A2 (fr) 2026-03-11
KR102534895B1 (ko) 2023-05-24
CN116751293A (zh) 2023-09-15
EP4706763A3 (fr) 2026-05-06
RS65633B1 (sr) 2024-07-31

Similar Documents

Publication Publication Date Title
FR24C1023I2 (fr) Anticorps thérapeutiques et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
EP3661965A4 (fr) Anticorps anti-cd47 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3283516A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3383904A4 (fr) Anticorps ctla-4 et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
EP3362482A4 (fr) Anticorps anti-pcsk9 et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
EP3411071A4 (fr) Nouveaux anticorps monoclonaux anti-cd 47 et leurs utilisations